Why drug developers that win the race to recruit more diverse patient populations to clinical trials will be the market leaders of the future
Are you tracking best practices in recruiting diverse patient populations as part of your clinical readiness strategy? Are health equity implications part of your routine Key Intelligence Questions?
To learn more, check out this article in Forbes from Brass Tacks' Principal Eileen Faucher on how drug developers that compete in these areas will be the market leaders in our increasingly diverse America.
https://lnkd.in/g-EdvShH